Clearside receives Nasdaq delisting notice; Chairperson Gibney resigns, Thorp succeeds

Clearside Biomedical, Inc.

Nasdaq notified Clearside on Aug 11, 2025 that its common stock is subject to delisting due to bid price below $1.00 for 30 consecutive business days.
Clearside intends to request a hearing before Nasdaq Panel to stay delisting; stock will continue trading pending hearing process.
Company is seeking stockholder approval for a reverse stock split at ratio 1-for-5 to 1-for-15 to regain minimum bid price compliance.
Anthony Gibney resigned as Chairperson and board member effective Aug 11, 2025; appointed CFO of Aura Biosciences; no dispute.
Board appointed existing member Clay B. Thorp as new Chairperson effective Aug 13, 2025.

item 3.01item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.